...Staff Writer Data presented at SITC last week provide preclinical proof of concept for Codiak’s IL-12... ...to deliver therapeutics that stay localized at the injection site. Lead candidate exoIL-12 displays functional IL-12... ...I/II testing for advanced solid tumors. Data are expected in mid-2021. TARGETSIL-12 – Interleukin-12
Codiak BioSciences Inc.
...monomer reduced disease scores, paw swelling and paw thickness, and improved locomotor activity.TARGET/MARKER/PATHWAY: Interleukin-12B (IL-12B); interleukin-12 receptor... ...Aug. 19, 2020doi:10.1073/pnas.2000653117CONTACT: Kalipada Pahan, Rush University Medical Center, Chicago, Ill.email: email@example.com
Rush University Medical Center
...another deal with BMS for nearly half a billion dollars up front covering a clinical IL-12... ...designed so other combination agents can be added. Initial data are expected in the fall.While IL-12... ...– Interleukin-12 PD-1 (PDCD1; CD279) – Programmed cell death 1
Elizabeth S. Eaton
Bristol Myers Squibb Co.
Dragonfly Therapeutics Inc.
...technology from the Massachusetts Institute of Technology. The newco’s lead program combines two cytokines -- IL-12... ...Inc. (NASDAQ:SRPT) in 2019. Hongjiang Li contributed to this report. Targets IL-2 Interleukin-2 IL-12 - Interleukin-12...
...then evaluated in combinations. Clackson said the B round will also go toward advancing Xilio’s IL-12... ...Targets CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 IL-2 - Interleukin-2 IL-12 - Interleukin-12...